source
- City Therapeutics raises $200 million in IPO to fund next-gen RNAi programsCity Therapeutics, a biotech focused on RNA interference, completed a $200 million initial public offering, selling about 11.1 million shares at $18 each. The proceeds will back three drug candida…
- Estuary Biotherapeutics raises $93 million Series A to develop gene therapies for ADPKDEstuary Biotherapeutics, a California gene‑therapy startup backed by Biogen, announced a $93 million Series A financing led by RA Capital. The capital will support development of two genetic medic…